Options: Show MedDRA Preferred Terms
Information about indications was extracted from the indications and usage sections of the labels.
Indication | Labels | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Breast cancer | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | |||
Breast cancer stage IV | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | |||
Cardiotoxicity | x | ||||||||||||||||||||
Colorectal cancer | x | x | x | x | x | x | x | x | x | x | x | ||||||||||
Colorectal cancer metastatic | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | ||||
Colorectal carcinoma | x | x | x | x | x | x | x | x | |||||||||||||
Hyperbilirubinaemia | x | ||||||||||||||||||||
Neoplasm | x | x | x | x | |||||||||||||||||
Neoplasm malignant | x | x | x | x | x | x | x | x | x | x | x | x | x | ||||||||
Renal impairment | x | x | x | x | x | x |
standard – alternative
100% | ||
75% | ||
50% | ||
10% | ||
frequent (1% to 100%) | ||
infrequent (0.1% to 1%) | ||
rare (<0.1%) | ||
postmarketing | ||
0% | ||
no frequency information | ||
not found on label |